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ABSTRACT (250 words) 
Background: In contrast with the setting of acute myocardial infarction, there are limited data 
regarding the impact of diabetes mellitus on clinical outcomes in contemporary cohorts of 
patients with chronic coronary syndromes. We aimed to investigate the prevalence and 
prognostic impact of diabetes according to geographical regions and ethnicity. 
Methods: CLARIFY is an observational registry of patients with chronic coronary syndromes, 
enrolled across 45 countries in Europe, Asia, America, Middle East, Australia and Africa in 
2009-2010, and followed-up yearly for 5 years. Chronic coronary syndromes were defined by ≥1 
of the following criteria: prior myocardial infarction, evidence of coronary stenosis >50%, 
proven symptomatic myocardial ischemia, or prior revascularisation procedure. 
Results: Among 32,694 patients, 9502 (29%) had diabetes, with a regional prevalence ranging 
from below 20% in Northern Europe to approximately 60% in the Gulf countries. In a 
multivariable-adjusted Cox proportional hazards model, diabetes was associated with increased 
risks for the primary outcome (cardiovascular death, myocardial infarction or stroke) with an 
adjusted hazard ratio of 1.28 (95% CI 1.18-1.39) and for all secondary outcomes (all-cause and 
cardiovascular mortality, myocardial infarction, stroke, heart failure and coronary 
revascularization). Differences on outcomes according to geography and ethnicity were modest. 
Conclusion: In patients with chronic coronary syndromes, diabetes is independently associated 
with mortality and cardiovascular events, including heart failure, which is not accounted by 
demographics, prior medical history, left ventricular ejection fraction, or use of secondary 
prevention medication. This is observed across multiple geographic regions and ethnicities, 
despite marked disparities in the prevalence of diabetes. 
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The global prevalence of diabetes has been rising rapidly and is estimated to have 
doubled since 1980, from 4.7% to 8.5% among adults.1 This unfavourable trend has been 
observed across a broad range of high and low income countries. 2,3  
Today, diabetes is the seventh cause of death worldwide.4 Age-standardized mortality 
rates attributable to high blood glucose are highest in the Middle East (which has by far the 
highest prevalence of diabetes worldwide), South-East Asia, and Africa.1 In patients without 
established cardiovascular disease, diabetes is associated with two-fold increase in the 
occurrence of a wide range of vascular disease independent of other risk factors.5,6 Among 
patients at high risk for or with established cardiovascular disease, 7–9 diabetes is independently 
increases the risk of death and cardiovascular events, including heart failure, by approximately 
30 to 40%.9 After acute myocardial infarction, short- and long-term mortality is higher among 
those with diabetes.10–12 In contrast, information is limited in the setting of chronic coronary 
syndromes. 
The use of various evidence-based therapies has improved outcomes following 
myocardial infarction, including in patients with diabetes.12–14 In the United States, all-cause 
mortality for patients with diabetes has been declining by 20% every 10 years since 1985, mainly 
driven by the reduction of death from vascular causes.15 Contemporary data regarding the 
worldwide prevalence of diabetes mellitus and its impact on clinical outcomes of patients with 
chronic coronary syndromes are needed. 
The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary 
arterY disease (CLARIFY) registry was established to describe the characteristics, management 
and outcomes of the broad contemporary spectrum of patients with chronic coronary 
6 
 
syndromes,16 which include patients with angina, myocardial ischemia or both, patients with 
previous history of myocardial infarction or history of coronary revascularization and patients 
with established coronary artery disease who may have no symptoms or ischemia.17 Patients with 
chronic coronary syndromes were enrolled from 45 countries in Europe, the Middle East, Asia, 
Northern, Central and South America, Australia and South Africa, and encompassed diverse 
ethnic origins. We aimed to describe the prevalence of diabetes among the ethnic and 
geographical regions, to evaluate the impact of diabetes on adverse cardiovascular outcomes 
among patients with chronic coronary syndromes, and to study whether the impact of diabetes 
differed according to region and ethnicity. 
 
METHODS 
Study design and subjects 
The design and overall results of the CLARIFY study have been described 
previously.18,19 Briefly, this international prospective observational registry enrolled stable 
patients, between November 26, 2009 and June 30, 2010, in whom coronary artery disease has 
been objectively documented by either previous myocardial infarction (>3 months), a previous 
coronary revascularization procedure (>3 months), coronary angiography (>50% stenosis) or 
myocardial ischemia provoked by functional testing in symptomatic individuals. Exclusion 
criteria were hospital admission for cardiovascular reasons (including revascularization) in the 
past 3 months, planned revascularisation, or conditions compromising the participation or 5-year 
follow-up (including severe other cardiovascular disease such as advanced heart failure, severe 
valve disease, or history of valve repair or replacement). The study was approved by local Ethics 
7 
 
Committees and/or Institutional Review Boards. All subjects provided written informed consent. 
The clinical trial registration number is ISRCTN43070564. 
 
Data collection 
Following recruitment of eligible subjects, demographic characteristics, medical history 
and current medications (medicines that were administered regularly for at least 7 days before 
inclusion) were obtained. Participation in the study did not affect routine clinical care and 
investigation, and participants were managed according to usual practice. No specific tests or 
treatment were mandated by the study protocol. Participants were followed regularly by at least 
an annual visit interspersed with telephone calls at 6 months, for 5 years. Major clinical events, 
such as death and its causes, myocardial infarction, stroke, coronary angiography and 
revascularization procedures as well as treatment were collected annually. 
Data were entered into electronic case report forms. Completeness, consistency and 
correctness were verified, managed and analyzed centrally by an independent academic statistics 
centre (Robertson Centre for Biostatistics, University of Glasgow, United Kingdom). 
Approximately 5% of the sites were randomly selected for audit and quality control. In those, 
site visits were conducted and 100% of data were source documents verified for all records. 
Baseline characteristics were obtained from the patient history and examination. Diabetes was 
defined as history of diabetes, or current diabetes, diagnosed by two fasting blood glucose 
measures >7 mmol/L or >126 mg/dL, or by an abnormal oral glucose tolerance test, 
independently of whether the subject received drug treatment for diabetes. Ethnicity was 
provided by the participant, and categorised as Caucasian, South Asians (those from the Indian 
subcontinent), East Asians (China or Korea/Japan), Hispanics, Black/Africans. In France and 
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Portugal, recording of ethnicity was not permitted by ethics committees and accounted for the 
majority of “unknown ethnicity”. To ascertain if there was geographical variation of outcomes of 
patients with diabetes, subjects were categorized into 6 geographical regions, Europe; Gulf 
countries; India; East and South-East Asia; Central and South America; and the United 
Kingdom, Canada, Australia and South Africa. The last four regions were grouped together 
based on the similarities of healthcare systems, and referred to as “commonwealth countries 
outside of Asia”.  
 
Outcomes 
For the purpose of this analysis, we defined the composite of cardiovascular death, 
myocardial infarction and stroke as the primary outcome of interest. Secondary outcomes were 
each component of the primary outcome, total death, and hospitalization for heart failure. The 
rate of coronary revascularization, either by percutaneous coronary intervention or coronary 
artery bypass grafting, was also studied in the analyses conducted in the total population. 
32,703 patients were enrolled in the CLARIFY registry, but information on diabetes was lacking 
in 9 patients, leaving 32,694 patients for the present analysis. 
 
Statistical Analysis 
Continuous variables are summarized as mean with standard deviation or median with 
interquartile range, as appropriate. Categorical variables are presented as numbers and 
percentages. Comparison of patients with and without diabetes were performed using chi-
squared tests or unadjusted analysis of variance, as appropriate. Confidence intervals for 
prevalence of diabetes per region, ethnicity, or country were calculated using binomial tests. 
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Cox proportional hazards models were used to assess the association between diabetes 
status and outcomes. In addition to crude hazard ratios (HRs), adjusted HRs were estimated after 
adjustment for potential confounding factors, selected a priori as potential confounders, namely 
age, sex, geographical region, smoking status, body-mass index, treated hypertension, baseline 
systolic blood pressure, estimated glomerular filtration rate (eGFR, calculated from the 
creatinine-derived chronic kidney disease Epidemiology Collaboration [CKD-EPI] equation20), 
previous myocardial infarction, previous percutaneous coronary intervention, previous coronary 
artery bypass grafting, number of diseased coronary vessels at baseline, peripheral artery disease 
at baseline, previous stroke or transient ischemic attack, previous hospital admission for (or 
symptoms of) heart failure, left ventricular ejection fraction, atrial fibrillation or flutter, and 
baseline drugs (any antiplatelet, statins, angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers, beta-blockers and diuretics). Interactions between diabetes and geographical 
regions were tested by introduction of product terms. Subgroup analyses, both crude and 
adjusted, were performed by geographical region and by ethnicity (for which the adjusted model 
did not include geography). 
Data were analyzed as recorded without imputation for missing data. Adjustment 
variables with a high number of missing data (eGFR, number of diseased coronary vessels and 
left ventricular ejection fraction) were analysed including a category for missing data to 
minimize the loss of data in the analysis. 
Statistical analyses were performed using R (3.4.1). 
 
RESULTS 
Prevalence of diabetes 
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 Among 32,694 participants, 9502 (29%) were found to have diabetes. There were marked 
disparities in the prevalence of diabetes across the 45 participating countries, ranging from 14% 
in Ireland (n=190) to 67% in Saudi Arabia (n=758) (Table S1). Across the various broad 
geographical regions, there was substantial heterogeneity in the prevalence of diabetes 
(P< 0.0001), which was highest in the Gulf Countries, with approximately 3 of 5 of participants 
affected, and lowest in Europe and Commonwealth countries outside of Asia (Canada, South 
Africa, United Kingdom and Australia), with approximately 1 of 4 participants affected (Figure 
1). Likewise, there was heterogeneity in the prevalence of diabetes according to self-reported 
ethnicity (P< 0.0001), although more modest, with a prevalence of nearly 40% in South Asians 
and Black/Africans and a prevalence 27 to 30% in Caucasian and East Asian patients. 
 
Baseline characteristics 
Baseline characteristics of the patients are reported in Table 1. Compared with patients 
without diabetes, patients with diabetes were older, and more often female. They were more 
likely to be obese and to have hypertension, performed less physical activity and had a lower 
education level, but were less likely to be current smokers and more likely to have LDL-
cholesterol level below 70 mg/dL. Compared with patients without diabetes, patients with 
diabetes were more likely to have peripheral artery disease, cerebrovascular disease, and a 
previous hospitalization for heart failure. Patients with diabetes were slightly less likely to have a 
history of percutaneous coronary intervention but markedly more likely to have undergone a 
coronary artery bypass grafting. Even though patients with diabetes were more likely to receive 
beta-blockers, their resting heart rate was higher. Thienopyridines, lipid lowering drugs, renin-
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angiotensin system blockers, calcium antagonists, and diuretics were more frequently prescribed 
to patients with diabetes. 
 
Clinical Outcomes 
After a median follow up of 5 years, 2807 patients met the primary outcome, and 2544 
patients died (1619 of cardiovascular cause). Stroke and myocardial infarction, occurred in 686 
and 1106 patients, respectively, 1647 patients were hospitalised for heart failure, and 2526 
underwent coronary revascularization.  
All adverse clinical outcomes occurred more frequently among patients with diabetes (Table 2). 
After statistical adjustment, the risk for the primary outcome (adjusted HR 1.28, 95% CI 1.18-
1.39), as well as the risks of all secondary outcomes remained higher for patients with diabetes 
(adjusted HR 1.38 [95% CI 1.27-1.50] for all-cause death, 1.39 [95% CI 1.25-1.54] for 
cardiovascular death, 1.26 [95% CI 1.10-1.43] for myocardial infarction, 1.29 [95% CI 1.09-
1.52] for stroke, 1.15 [95% CI 1.03-1.28] for hospital admission for heart failure, and 1.14 [95% 
CI 1.04-1.25] for coronary revascularization) 
The rates of 5-year clinical outcomes in patients with and without diabetes across 
geographical regions are shown in Table 3. Despite the marked geographical disparities in the 
prevalence of diabetes, the prognostic value of diabetes after adjustment for potential 
confounders was similar across geographical regions, and interaction between diabetes and 
geography was non-significant for all outcomes (Table 3).  
The rates of 5-year clinical outcomes in patients with and without diabetes across ethnic 
groups are shown in Table S2. The highest crude and adjusted risk associated with diabetes for 
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the primary outcome and for cardiovascular and all-cause death was observed for South Asians, 
the majority of whom were of Indian origin.  
Of note, the higher rate of hospitalization for heart failure in patients with versus without 
diabetes was observed consistently across the geographical regions and ethnic groups, except for 
subgroups in whom the number of events was too low for a reliable estimate of the risk, as 
shown by wide confidence intervals (Table 3 and Table S2).  
 
DISCUSSION 
In this large contemporary international registry of patients with chronic coronary 
syndromes, the prevalence of diabetes was 29%, much higher than in the general population in 
which the estimated prevalence is approximately 8-10%.1,2  
Data on the prevalence of diabetes in the population of patients with chronic coronary 
syndrome across multiple regions are scarce, especially from “real-life” international registries. 
In the Diabetes and Heart survey, a multi-centre European prospective observational study 
conducted in 25 countries (enrolment 2003-2004), the prevalence of diabetes was 31%, and was 
similar in patients recruited after acute admissions or elective consultations.21 In the large-scale 
Swedish registry of patients with a primary myocardial infarction recruited from 2006 to 2011,22 
the prevalence of diabetes was 23% both in the total population and in the stable population who 
survived for 12 months without a subsequent myocardial infarction or stroke, reflecting the 
relatively lower prevalence of diabetes in Europe (especially northern Europe) than in other 
regions of the world. In the subgroup of patients with coronary artery disease (n=26389) from the 
Reduction of Atherothrombosis for Continued Health (REACH) registry, which recruited 
patients 6 years earlier that CLARIFY, 38% had diabetes.9 The majority of contemporary data on 
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the prevalence of diabetes in chronic coronary syndromes arise from randomized trials. In the 
Study Assessing the Morbidity–Mortality Benefits of the If  Inhibitor Ivabradine in Patients with 
Coronary Artery Disease (SIGNIFY) trial,23 which recruited patients with stable coronary artery 
disease of at least 55 years of age, during the same time period as CLARIFY, the prevalence of 
diabetes was 43%. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies 
(COMPASS) trial (recruitment 2013-2016), the prevalence of diabetes in the 24824 patients with 
coronary artery disease at baseline was 37%.24 Interestingly, in one of the most recent reported 
population with stable coronary artery syndromes, the International Study of Comparative Health 
Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial, in which patients were 
randomly assigned to revascularization or optimal medical therapy, the prevalence of diabetes 
was 41%.25 Overall, although the prevalence of diabetes may vary depending on the recruitment 
period, proportion of women, mean age and geographical origins of study participants, the 
prevalence of this comorbidity is extremely high in patients with coronary artery disease. 
Noteworthy, in all these studies as well as ours, since oral glucose tolerance tests were not 
systematically performed to screen for diabetes, the true prevalence of diabetes was very likely 
underestimated, as shown by studies from the Euro Heart Survey 21 and from the European 
Society of Cardiology surveys European Action on Secondary and Primary Prevention by 
Intervention to Reduce Events (EUROASPIRE) IV26 and V.27 
 
In our study, there were considerable disparities in the prevalence of diabetes across 
different geographical regions. There were also disparities among ethnic groups, with a high 
prevalence observed in South Asians. While the prevalence of diabetes is rising worldwide, the 
rate of increase varies considerably across geographical regions. The increase in the prevalence 
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of diabetes is higher in low and middle-income countries, and especially high among developing 
Asian countries in which prevalence may nowadays exceed by far that observed in some 
developed countries.1,28 Accordingly, we found that the prevalence of diabetes was highest in 
Asian regions, particularly in the Middle East and India. Our data which showed a prevalence of 
60% in the Gulf Countries confirms reports of the World Health Organization warning that the 
Eastern Mediterranean Region has been experiencing the greatest rise in diabetes prevalence in 
the past decade and is now the region with the highest prevalence of diabetes.1. Such high rates 
of diabetes in those regions considered as the epicentre of the epidemic may be attributed to the 
rising affluence, urbanization and the associated changes in lifestyle.28 Increasing and 
westernization of food intake together with reduction in physical activity could explain part of 
this adverse trend.29,30 This is best illustrated by the substantial increase of childhood obesity.28 
Genetic variants may also predispose to the increasing prevalence of diabetes in the Middle East 
and Asia,31 with a higher proportion of body fat and abdominal obesity in Asian people 
compared to people of European origin for similar body mass index.32,33 Conversely, we 
observed the lowest prevalence in Northern Europe and Commonwealth countries outside of 
Asia. Through comprehensive and integrated public health approach including well-targeted 
education programs, other countries have been made more aware of the benefits of healthy living 
and modified their lifestyle to promote better health.  
The definition of ethnicity is challenging, particularly when the number of inter-ethnic 
and inter-national marriages is increasing, so that geographical regions may provide a more 
stable cross-sectional assessment. Therefore, geographical region, rather than ethnicity, was 
included in the multivariable adjusted model. Geographical regional approach is however 
confronted with its unique set of challenges in today’s world of global migration, with 
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individuals of the same regions having markedly different customs, practices, and beliefs. 
Prevalence of diabetes differed to a larger extent across geographical regions than ethnicities. 
Independently of their ethnicity, patients tend to be exposed to the norms and customs of their 
host countries and to adopt the practices of the country they live in. Accordingly, it has been 
shown that with increasing duration of residence, migrants in the United States were more likely 
to display a higher prevalence of cardiometabolic risk factors.34 
Overall, as underscored by the World Health Organization, the particularly high 
prevalence of diabetes measured in some regions highlight the need for strong public action and 
implementation of programs targeting groups of people at high-risk to oppose the rising trend of 
diabetes. Research on the epidemiology of diabetes needs to be combined with efforts in primary 
prevention of diabetes – weight control and exercise being the first steps –, early detection of the 
disorder, and improved management of patients with established diabetes, both at the individual 
level and through health system interventions.28,35 
 
Our study provides important data on the magnitude of associations of diabetes with 
adverse outcomes in a contemporary registry of patients with chronic coronary syndromes. After 
adjustment for multiple potential confounders, patients with diabetes and with stable coronary 
artery disease had a significantly increased risk for all adverse events. The adjusted HR for 
patients with diabetes versus those without diabetes for the composite outcome of cardiovascular 
death, myocardial infarction or stroke was 1.28 (95% CI 1.18, 1.39). Of note, the total mortality 
rates were10.5% and 6.8%in patients with and without diabetes, respectively. Interestingly, as 
previously observed in the REACH registry,9 our results showed that the rate of hospitalization 
for heart failure was significantly higher in patients with diabetes, even after adjusting for 
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baseline heart failure symptoms and left ventricular ejection fraction. In the SIGNIFY trial, the 
incidence of the primary endpoint (cardiovascular death or non-fatal myocardial infarction) was 
1.27 times higher (in the placebo arm) in those with diabetes after a median follow up of 28 
months.23 Patients with diabetes had a 1.40 to 1.50 increased risk for the composite of 
cardiovascular death, myocardial infarction, or stroke, depending on treatment arm, in the 
COMPASS trial, and this was true in the total population36 as well as in patients with coronary 
artery disease.24 Interestingly, in the recent ISCHEMIA trial, those with diabetes had one of the 
highest estimated 5-year cardiovascular event rate (primary outcome, defined as of death from 
cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, 
or resuscitated cardiac arrest), which was 1.30 to 1.38 times higher than in those without 
diabetes.37 These contemporary data from randomized trials corroborate our results obtained in a 
registry. These large complementary sets of data provide an accurate picture of the increased risk 
associated with diabetes nowadays. 
Overall, patients with diabetes remain at high risk of adverse cardiovascular events. This 
is true worldwide, across geographic regions and ethnicities, although the challenge is even 
greater in some regions where the prevalence of diabetes is extremely high such as the Middle 
East. In parallel with worldwide efforts to reduce overweight, obesity, physical inactivity and 
unhealthy diets responsible for the rising prevalence of diabetes, new and improved therapies to 
address the cardiovascular consequences of diabetes are direly needed. Sodium-glucose 
cotransporter-2 (SGLT-2) inhibitors38 and glucagon-like peptide-1 receptor agonist39 appear to 
impact adverse cardiovascular outcomes in this group of patients.40 Notably, SGLT-2 inhibitors 
have been shown to reduce cardiovascular death and hospitalization for heart failure among 
patients with or without cardiovascular disease and with or without a history of heart failure.38,41 
17 
 
Recently, SGLT-2 inhibitors have even been shown to reduce cardiovascular mortality and 
hospitalization for heart failure when initiated soon after an episode of decompensated heart 
failure.42 These improvements are particularly relevant in the context of our finding that patients 
with diabetes were more likely to be hospitalized for heart failure. In addition, SGLT-2 inhibitors 
have been shown to have a marked benefit for kidney disease progression in patients with 
diabetes.41,43 Of note, disparities in access to these lifesaving therapies will likely further drive 
regional differences over time until generic access is widely available. 
Beyond glycaemic control, other secondary prevention therapies need to be optimized. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab44 and 
alirocumab,45 reduce low-density lipoprotein cholesterol level more than statins alone, and have 
the potential to improve outcomes of patients with dyslipidaemia, with and without diabetes, 
particularly in very high-risk patients. Likewise, newer evidence-based potent antiplatelet agents 
may also lower cardiovascular event rates in diabetic patients with chronic coronary 
syndromes.46 In the Cardiovascular Outcomes for People Using Anticoagulation Strategies 
(COMPASS) trial, it has been recently shown that the concomitant use of low-dose oral direct 
thrombin inhibitors in addition to antiplatelet agents further improves outcome among patients 
with diabetes36,47. 
Although the rates of evidence-based secondary prevention medicines were very high in 
our registry of patients with coronary disease, risk factor management could be further improved, 
has shown by data on physical activity, by the high rate of patients with uncontrolled blood 
pressure, and levels of LDL-cholesterol above target. Likewise, it was recently shown in the 
large European Survey EUROASPIRE V that management of diabetes in patients with coronary 
artery disease was far from optimal.27,48 In addition, many of the above-mentioned newer 
18 
 
improved therapies – in particular SGLT-2 inhibitors – were not available during the conduct of 
this study, and may contribute to improve cardiovascular outcomes in diabetes in the coming 
years. In our study, patients with diabetes were more likely to undergo coronary 
revascularization. This finding suggested that they were treated aggressively. However, our data 
were unable to ascertain to what extent these procedures followed a higher rate of ischemic 
events or prevented an otherwise higher rate of ischemic events. Information on the use of drug-
eluting stents was not collected in the registry.  
 
 Although CLARIFY was a large global prospective study, participants were enrolled 
from clinics which were not randomly allocated. Therefore, our findings may not accurately 
reflect the epidemiology of each country. Furthermore, ethnicity was self-reported, which may 
have affected the accuracy of the data, and it was unknown in about 10% of the population, 
mainly due to statutory regulations, specifically in France and Portugal. In addition, we did not 
separate type 1 and type 2 diabetes, although the prevalence of the latter was likely most 
common, and our study was not designed to analyse the effect of diabetic medication, which 
were not extensively collected beyond insulin versus oral agents. Finally, endpoints were not 
adjudicated by an independent blinded committee; however they were reported by physicians 
according to the detailed requirement of case report forms and onsite monitoring visits were 
conducted in randomly selected centres with source verification of events. Therefore, we believe 
that despite these limitations, our results provided valuable insight into the prevalence and 





In conclusion, in this global registry of patients with chronic coronary syndromes, overall 
prevalence of diabetes was 29%, with marked disparities across geographical regions which 
reflect those reported by the Word Health Organization in the general population. Patients with 
diabetes and coronary artery disease have a markedly increased risk of cardiovascular events, 
independently of multiple confounding factors, and this is true across all geographical regions 
and ethnicities. Improved strategies to slow the progression of diabetes and more effective 
intervention to prevent its adverse consequences through lifestyle modification, revascularisation 
procedures and pharmacological therapies, are direly needed. 
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Prevalence of diabetes across various geographic regions and ethnic groups 
 
 










Diabetes No diabetes 
p-value 
(n = 9502) (n = 23192) 
Age (years) 32679 65.0 (9.7) 63.8 (10.7) <0.0001 
Men 32684 7099 (74.8 %) 18259 (78.7 %) <0.0001 
Body mass index (kg/m²) 32651 28.9 (4.9) 27.4 (4.3) <0.0001 
Obesity (Body mass index ≥ 30 kg/m²) 32651 3443 (36.3%) 5510 (23.8%) <0.0001 
Smoking status 32693 
  
<0.0001 
Current - 997 (10.5%) 3080 (13.3%) - 
Former - 4205 (44.3%) 10902 (47.0%) - 
Never - 4299 (45.2%) 9210 (39.7%) - 
Treated hypertension 32689 7756 (81.7%) 15450 (66.6%) <0.0001 
Systolic blood pressure (mm Hg) 32667 132.7 (17.1) 130.4 (16.4) <0.0001 
Diastolic blood pressure (mm Hg) 32667 76.8 (10.1) 77.4 (9.9) <0.0001 
Blood pressure ≥ 140/90 mmHg 32667 3651 (38.5%) 7857 (33.9%) <0.0001 
Heart rate (beats/minute) 32665 70.2 (10.9) 67.4 (10.4) <0.0001 
Geographical region 32694     <0.0001 
   Europe 
 
4809 (50.6%) 13513 (58.3)   
Gulf countries 
 
902 (9.4%) 606 (2.6%)   
   India 
 
304 (3.2%) 405 (1.7%)   
   East and South-East Asia 
 
1464 (15.4%) 3515 (15.2%)   
   Central and South America 
 
811 (8.5%) 1418 (6.1%)   
Commonwealth (outside of Asia)*   1212 (12.7%) 3735 (16.1%)   
Education 32687     <0.0001 
   Primary school (or less) 
 
3100 (32.6%) 5546 (23.9%)   
   Secondary school 
 
4229 (44.5%) 10,972 (47.3%)   
   College/University   2170 (22.8%) 6670 (28.8%)   
Weekly Physical Activity 32684 
 
  <0.0001 
   None 
 
2061 (21.7%) 3226 (13.9%)   
   Only light 
 
4999 (52.6%) 11808 (50.9%)   
   Vigorous at least once or twice 
 
1260 (13.3%) 4209 (18.2%)   
   Vigorous 3 or more times 
 
1176 (12.4%) 3945 (17.0%)   
Myocardial Infarction 32689 5601 (59.0%) 13988 (60.3%) 0.0266 
Percutaneous coronary intervention 32688 5471 (57.6%) 13686 (59.0%) 0.0197 
Coronary artery bypass graft surgery 32688 2608 (27.5%) 5092 (22.0%) <0.0001 
Peripheral artery disease 32694 1360(14.3) 1879 (8.1) <0.0001 
Transient Ischemic Attack 32691 339 (3.6%) 662 (2.9%) 0.0008 
Stroke 32692 516 (5.4%) 798 (3.4%) <0.0001 
Atrial fibrillation/flutter 32693 635 (6.7%) 1677 (7.2%) 0.0837 
Hospitalization for heart failure 32693 640 (6.7%) 890 (3.8%) <0.0001 
Symptoms of heart failure 32686 1414 (14.9%) 3511 (15.1%) 0.5783 
Left ventricular ejection fraction (%) 22514 54.7 (11.5) 56.7 (10.8) <0.0001 
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HbA1C in patients with diabetes (%) 5121 7.3 (1.8) - - 
eGFR (mL/min/1.73m²) 22166 73.1 (20.9) 76.1 (18.7) <0.0001 
Total cholesterol (mmol/L) 26297 4.3 (1.1) 4.4 (1.1) <0.0001 
HDL-cholesterol (mmol/L) 23267 1.1 (0.3) 1.2 (0.3) <0.0001 
LDL-cholesterol (mmol/L) 22131 2.4 (0.9) 2.5 (0.9) <0.0001 
LDL-cholesterol ≥ 1.8 mmmol/L (70 mg/dL) 22131 4828 (73.8%) 12684 (81.3%) <0.0001 
Fasting triglycerides (mmol/L) 24141 1.8 (1.0) 1.5 (0.8) <0.0001 
Baseline medication 
   
  
Insulin in patients with diabetes 9497 2048 (21.6%) - - 
Aspirin 32681 8350 (87.9%) 20329 (87.7%) 0.5435 
Thienopyridine 32546 2806 (29.6%) 6073 (26.2%) <0.0001 
Other antiplatelet agent 32652 924 (9.7%) 2098 (9.1%) 0.0554 
Lipid-lowering drugs 32684 8889 (93.6%) 21,294 (91.8%) <0.0001 
Beta-blockers 32685 7349 (77.4%) 17256 (74.4%) <0.0001 
Calcium antagonists 32680 3149 (33.2%) 5757 (24.8%) <0.0001 
Angiotensin-converting enzyme inhibitors 32683 4995 (52.6%) 11895 (51.3%) 0.0347 
Angiotensin II receptor antagonists 32677 3098 (32.6%) 5574 (24.0%) <0.0001 
Diuretics 34681 3683 (38.8%) 5902 (25.5%) <0.0001 
 
Data are mean (SD) or number (%). Some percentages do not add up to 100 because of rounding. eGFR=Glomerular 
Filtration Rate estimated from the CKD-EPI equation; NYHA=New York Heart Association (NYHA) Functional 
Classification; HDL cholesterol=high-density lipoprotein cholesterol; LDL cholesterol=low-density lipoprotein 
cholesterol. 




Table 2: Five-year event rates and crude and adjusted hazard ratios (95% CI) by diabetes 
status 
 
  Diabetes No diabetes p-value 
Cardiovascular death, myocardial infarction or stroke   
event rate (n/N, %) 1035/9393 (11.0%) 1772/22985 (7.7%)   
unadjusted HR 1.48 (1.37, 1.60) 1.00 (-) <0.0001 




event rate (n/N, %) 990/9393 (10.5%) 1554/22985 (6.8%)   
unadjusted HR 1.61 (1.48, 1.74) 1.00 (-) <0.0001 




event rate (n/N, %) 650/9393 (6.9%) 969/22985 (4.2%)   
unadjusted HR 1.69 (1.53, 1.87) 1.00 (-) <0.0001 
adjusted HR 1.39 (1.25, 1.54) 1.00 (-) <0.0001 
Myocardial infarction (fatal or not) 
 
  
event rate (n/N, %) 390/9393 (4.2%) 716/22985 (3.1%)   
unadjusted HR 1.37 (1.21, 1.55) 1.00 (-) <0.0001 
adjusted HR 1.26 (1.10, 1.43) 1.00 (-) 0.0007 
Stroke (fatal or not) 
  
  
event rate (n/N, %) 252/9393 (2.7%) 434/22985 (1.9%)   
unadjusted HR 1.47 (1.26, 1.71) 1.00 (-) <0.0001 
adjusted HR 1.29 (1.09, 1.52) 1.00 (-) 0.0024 
Hospital admission for heart failure     
event rate (n/N, %) 608/9064 (6.7%) 1039/22280 (4.7%)   
unadjusted HR 1.49 (1.35, 1.65) 1.00 (-) <0.0001 




event rate (n/N, %) 804/9070 (8.9%) 1722/22282 (7.7%)   
unadjusted HR 1.18 (1.09, 1.28) 1.00 (-) <0.0001 
adjusted HR 1.14 (1.04, 1.25) 1.00 (-) 0.0035 
 
HR= hazard ratio; 95% CI=95% confidence interval 
n/N=number of events/number of patients 
Covariates for the adjusted model: age, sex, geographical region, smoking status, body-mass index, treated 
hypertension, baseline systolic blood pressure, eGFR, previous myocardial infarction, previous percutaneous 
coronary intervention, previous coronary artery bypass grafting, number of diseased coronary vessels at baseline, 
peripheral artery disease at baseline, previous stroke or transient ischemic attack, previous hospital admission for (or 
symptoms of) heart failure, left ventricular ejection fraction, atrial fibrillation or flutter, and baseline drugs (any 








Table 3. Five-year outcomes by diabetic status within geographical subgroups 
 
  n/N (event rates, %)   HR (95% CI)   
  Diabetes No diabetes   (Diabetes vs no diabetes) p-value 
Cardiovascular death, myocardial infarction or stroke 
   
0.7964$ 
Europe 559/4776 (11.7%) 1019/13426 (7.6%) 
 
1.29 (1.15, 1.44) <0.0001 
Gulf countries 81/890 (9.1%) 41/603 (6.8%) 
 
1.40 (0.93, 2.11) 0.1061 
India 28/303 (9.2%) 21/403 (5.2%) 
 
1.51 (0.80, 2.84) 0.2010 
East Asia 122/1462 (8.3%) 211/3498 (6.0%) 
 
1.32 (1.05, 1.66) 0.0194 
Central and South America 98/788 (12.4%) 125/1382 (9.0%) 
 
1.34 (1.01, 1.78) 0.0415 
Commonwealth (outside of Asia) 147/1174 (12.5%) 355/3673 (9.7%)   1.18 (0.96, 1.45) 0.1222 
Cardiovascular death 
    
0.5342$ 
Europe 355/4776 (7.4%) 549/13426 (4.1%) 
 
1.42 (1.23, 1.63) <0.0001 
Gulf countries 55/890 (6.2%) 27/603 (4.5%) 
 
1.31 (0.79, 2.19) 0.2929 
India 23/303 (7.6%) 16/403 (4.0%) 
 
1.58 (0.75, 3.31) 0.2263 
East Asia 65/1462 (4.4%) 96/3498 (2.7%) 
 
1.59 (1.15, 2.21) 0.0055 
Central and South America 67/788 (8.5%) 90/1382 (6.5%) 
 
1.21 (0.86, 1.71) 0.2726 
Commonwealth (outside of Asia) 85/1174 (7.2%) 191/3673 (5.2%)   1.22 (0.92, 1.60) 0.1646 
All-cause death 
    
0.0887$ 
Europe 547/4776 (11.5%) 893/13426 (6.7%) 
 
1.41 (1.26, 1.58) <0.0001 
Gulf countries 85/890 (9.6%) 34/603 (5.6%) 
 
1.65 (1.07, 2.55) 0.0246 
India 34/303 (11.2%) 22/403 (5.5%) 
 
1.83 (1.00, 3.35) 0.0495 
East Asia 101/1462 (6.9%) 153/3498 (4.4%) 
 
1.55 (1.19, 2.01) 0.0010 
Central and South America 87/788 (11.0%) 127/1382 (9.2%) 
 
1.05 (0.79, 1.41) 0.7289 
Commonwealth (outside of Asia) 136/1174 (11.6%) 325/3673 (8.8%)   1.20 (0.97, 1.49) 0.0955 
Myocardial infarction (fatal or not) 
    
0.9537$ 
Europe 187/4776 (3.9%) 388/13426 (2.9%) 
 
1.24 (1.03, 1.49) 0.0213 
Gulf countries 32/890 (3.6%) 13/603 (2.2%) 
 
1.41 (0.71, 2.81) 0.3228 
India 10/303 (3.3%) 10/403 (2.5%) 
 
1.08 (0.38, 3.06) 0.8825 
East Asia 41/1462 (2.8%) 82/3498 (2.3%) 
 
1.13 (0.77, 1.67) 0.5376 
Central and South America 49/788 (6.2%) 57/1382 (4.1%) 
 
1.58 (1.05, 2.37) 0.0270 
Commonwealth (outside of Asia) 71/1174 (6.0%) 166/3673 (4.5%)   1.26 (0.93, 1.69) 0.1341 
Stroke (fatal or not) 
    
0.9180$ 
Europe 141/4776 (3.0%) 256/13426 (1.9%) 
 
1.26 (1.01, 1.56) 0.0385 
Gulf countries 13/890 (1.5%) 5/603 (0.8%) 
 
2.88 (0.88, 9.39) 0.0803 
India 4/303 (1.3%) 2/403 (0.5%) 
 
- - 
East Asia 43/1462 (2.9%) 78/3498 (2.2%) 
 
1.30 (0.88, 1.90) 0.1889 
Central and South America 22/788 (2.8%) 22/1382 (1.6%) 
 
1.45 (0.77, 2.72) 0.2471 
Commonwealth (outside of Asia) 29/1174 (2.5%) 71/3673 (1.9%) 
 
1.20 (0.75, 1.90) 0.4496 
Hospital admission for heart failure         0.7817$ 
Europe 402/4632 (8.7%) 765/13057 (5.9%) 
 
1.14 (1.00, 1.30) 0.0453 
Gulf countries 42/868 (4.8%) 20/586 (3.4%) 
 
1.45 (0.80, 2.61) 0.2194 
India 11/299 (3.7%) 11/393 (2.8%) 
 
0.82 (0.31, 2.17) 0.6916 
East Asia 63/1409 (4.5%) 93/3391 (2.7%) 
 
1.57 (1.12, 2.18) 0.0082 
Central and South America 38/746 (5.1%) 47/1324 (3.5%) 
 
1.10 (0.69, 1.77) 0.6902 
Commonwealth (outside of Asia) 52/1110 (4.7%) 103/3529 (2.9%)   1.16 (0.81, 1.68) 0.4193 
 
HR= hazard ratio; 95% CI=95% confidence interval 
Commonwealth countries in CLARIFY are Canada, South Africa, Australia and United Kingdom 
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Covariates the adjusted subgroup models: age, sex, smoking status, body-mass index, treated hypertension, baseline 
systolic blood pressure, eGFR, previous myocardial infarction, previous percutaneous coronary intervention, 
previous coronary artery bypass grafting, number of diseased coronary vessels at baseline, peripheral artery disease 
at baseline, previous stroke or transient ischemic attack, previous hospital admission for (or symptoms of) heart 
failure, left ventricular ejection fraction, atrial fibrillation or flutter, and baseline drugs (any antiplatelet, statins, 
angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers and diuretics). 
$ p-value for interaction between geographical region and diabetes (adjusted model) 
 
 
 
